Serotonin-5-O-carboxymethyl-glycyl[125I]tyrosinamide labels the 5-HT1D beta receptor subtype in human cortex.
This study, carried out in human cerebral cortical membranes, confirms previous findings in human substantia nigra that serotonin-5-O-carboxymethyl-glycyl[125I]tyrosinamide ([125I]GTI) labels a homogeneous population of recognition sites consistent with a 5-HT1D receptor pharmacology. In addition the results indicate that, under the assay conditions described, [125I]GTI specifically labels the 5-HT1D beta recognition site since ketanserin and ritanserin display a low affinity consistent with their activities at this subtype of the 5-HT1D receptor.